As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n ¼ 7) and unrelated donors (n ¼ 22). Tacrolimus was given orally from day À1 to achieve trough blood levels of 5-10 ng/ml. MMF was started on day 0 at 1500 mg intravenously b.i.d. AUC measurements of MPA by HPLC were scheduled on days 3, 7 and 11 after transplantation. The MMF dose was modified to achieve an MPA AUC of 35-60 lg/ml/h. With the respective adjustments 66 and 75% surpassed the lower AUC target on days 7 and 11, respectively. The cumulative incidence of grade III-IV acute GVHD was 28% (8/29). Eight out of 24 evaluable patients (33%) suffer from limited (n ¼ 3) or extensive (n ¼ 5) chronic GVHD. Overall, the results of this study suggest that targeting of MPA exposure is feasible early after transplantation. A simplified MMF targeting strategy based on MPA C max or C 2h levels seems to be warranted in future trials involving more patients at later time points in the outpatient setting.
Introduction
Allogeneic hematopoietic SCT (HSCT) is performed with increasing frequency in the effort to cure patients with malignant hematological diseases. GVHD, one of the major risk factors after allogeneic transplantation, contributes to a transplant-related mortality of 15-30%. 1 To reduce GVHD-related mortality, prophylactic and therapeutic immunosuppressive regimen including mycophenolate mofetil (MMF) have been investigated in clinical studies. [2] [3] [4] [5] One principal motivation of most investigators was to replace MTX by MMF to reduce the risk of mucosal, hematological and hepatic side effects associated with MTX.
Mycophenolate mofetil is successfully used since 1995 for the prevention of renal allograft rejection. Combined with CsA, MMF reduced the rate of renal allograft rejection episodes during the first year significantly. 6 The bioavailability reported for MMF in healthy individuals is 94%. After absorption, MMF is rapidly hydrolyzed by esterases to the active compound mycophenolic acid (MPA). The hepatic glucuronidation of MPA by glucuronosyl transferase to MPA glucuronide (MPAG) is followed by an excretion of MPAG in bile. MPAG is deconjugated by colonic bacteria back to MPA and reabsorbed to systemic circulation. Finally, over 48 h post-dose more than 71% of the administered dose undergoes renal elimination as MPAG.
Mycophenolic acid inhibits the inosine monophosphate dehydrogenase, which is the key enzyme in the pathway of de novo purine synthesis. In contrast to other cells, T and B lymphocytes rely on this pathway to synthesize guanosine-5 0 -triphosphate and dGTP, which are essential for DNA synthesis. In this way, the administration of MMF leads to selective inhibition of T-and B-cell proliferation. Because GVHD is predominantly mediated by donor T cells, MMF might have additive effects to standard immunosuppressive drugs for GVHD prophylaxis. Recent clinical studies support the hypothesis that higher cumulative doses and shorter dosing intervals seem to reduce the risk for acute GVHD at the expense of a moderate increase in unwanted side effects. 7 In previous studies, we investigated MMF after oral and i.v. administration in combination with CsA as GVHD prophylaxis after allogeneic blood SCT from HLAcompatible related and unrelated donors. 3, 8 No severe side effects and adverse events were observed. Compared to a control group receiving MTX and CsA, we saw no significant differences in the mucosal and intestinal toxicities and in the incidence of acute GVHD. However, measured trough plasma levels and the area under the concentration (AUC) vs time curve of MPA and MPAG after both routes of administration were much lower than measured in recipients of solid organ transplants or in healthy individuals. 9, 10 But still, the i.v. application of MMF at increasing dose levels was associated with an increase in AUC and a certain accumulation of MPA and MPAG over 3-4 weeks of therapy. A possible explanation for the decreased levels of MPA after oral administration could have been a reduced absorption rate caused by intestinal toxicity after high-dose conditioning. It is also conceivable that the enterohepatic recirculation of MPA was impaired by several factors. Given the metabolism and the elimination of the compound, a significant interpatient variability can be assumed. In addition, the clinical status as well as the organ function of recipients of allo-HSCT is prone to significant variation according to the intensity of conditioning, mucositis, infections and the occurrence of GVHD.
To account for most of these factors, we performed a pilot trial in which we aimed at infusing MMF at doses required to achieve a certain AUC target to individualize the exposition of patients toward the active metabolites of MMF.
Patients and methods
The patient's and treatment characteristics are summarized in Table 1. Between July 2004 and January 2006 29 patients  (17 male, 12 female) with a median age of 53 (range, 21-69) years were included. Diagnosis included myelodysplastic syndrome/chronic myelomonocytic leukemia (n ¼ 8), de novo AML (n ¼ 11), non-Hodgkin's lymphoma (n ¼ 6), Hodgkin's lymphoma (n ¼ 2) and multiple myeloma (n ¼ 2). Cytogenetic risk categories for all AML and myelodysplastic syndrome patients are provided in Table 1 . Informed consent was obtained in all cases and was documented using forms approved by the Institutional Review Board.
Conditioning therapy
The preparative regimen included 30 mg/m 2 fludarabine infused over 30 min on days -9 to -6 (total dose 120 mg/m 2 ) followed by i.v. BU at 3.45 mg/kg infused over 2 h from days -5 to -2 (total dose 13.8 mg/kg i.v.). The regimen was adapted according to a phase II study in which CY was replaced by fludarabine combined with a targeted dose of oral BU. 11 In a pilot study, we could show that intra-and interpatient variability can be significantly reduced by using i.v. BU with minimal dose adjustments. 12 
GVHD prophylaxis
The prophylactic regimen consisted of a combination of tacrolimus with targeted MMF. Tacrolimus with MMF had been described previously to induce a higher AUC of MPA compared to CsA/MMF in solid organ transplant recipients. 13 According to the current hypothesis, CsA leads to a more profound blockade of biliary secretion of MPAG, which inhibits secondary reabsorption of the compound. According to the protocol, tacrolimus was given orally starting on day -1 at 0.03 mg/kg split into two doses to achieve trough blood levels of 5-10 ng/ml. We used a minimally lower target level for tacrolimus compared to other investigators to avoid excess toxicity when escalating Targeting mycophenolate mofetil for GVHD prophylaxis I Haentzschel et al MMF doses. 14 In case of mucositis, nausea or patient preference, tacrolimus was administered intravenously during their stay at hospital. MMF (Cellcept) was started on day 0 at 1.5 g intravenously b.i.d. The dose adjustments were scheduled after the respective days of MPA AUC measurements and were calculated according to a linear model. Flat dosing of the initial MMF application was chosen instead of a body weight-based regimen because dose optimization was already expected to occur on day 4. Patients were switched to the oral formulations of tacrolimus and MMF before discharge. Oral MMF was dosed equivalently to the last targeting level and continued until day 56. If no GVHD had occurred, MMF was gradually decreased until day 84. Tacrolimus was gradually decreased starting on day 120 with the goal to be off medication around day 180. In case of acute GVHD Xgrade II, patients received therapy with prednisolone at 2 mg/kg for 5-7 days with a decrease after clinical response. Steroid-refractory GVHD was either treated with anti-TNF-a antibodies (infliximab) or pentostatin.
Donor selection and blood stem cell harvest Related or unrelated donors were selected on the basis of compatibility for HLA-A, -B, -C, DRB1 and DQB1 by intermediate or high-resolution DNA typing. Mismatch for a single HLA-A, -B, -C, DRB1 and DQB1 allele was allowed within the same broad serotype (that is, A*0101 vs 0102) or within a crossreactive group (that is, A*0101 vs 0301). Data are summarized in Table 1 . Female donors had to be chosen in five cases.
Injection of the donor with G-CSF and apheresis were performed according to the policy of the collection center. PBSCs were stored overnight at 4 1C when necessary. A target dose of 44.0 Â 10 6 CD34 þ cells per kg were requested. The dose of infused CD34 þ and CD3 þ cells is shown in Table 1 . Blood stem cells were infused on day 0 without further manipulation.
Pharmacokinetic studies of MPA, MPAG and MPA targeting On days 3, 7 and 11 after transplantation, AUC measurements of MPA were performed. Blood samples were collected at 0, 0.5, 2, 3, 4, 7, 9 and 12 h after start of the 2 h MMF infusion. Details of the chemical and pharmacokinetic analyses for MPA and MPAG have been described. 15 Briefly, after organic extraction the compounds were separated on a Spherisorb ODS-2 column (Waters, Eschborn, Germany) followed by post-column derivatization. Chromatograms were detected with Fluorescence Spectroscopy. The amounts of MPA and the MPAG were evaluated from peak areas.
The modification of the actual MMF dose was planned to be adjusted 24 h after the preceding pharmacokinetic assessment. If the AUC achieved was less than 35 or more than 60 mg/ml/h, subsequent doses were adjusted to a proportional approximation: old dose Â target MPA-AUC/ measured MPA-AUC. This target level was adapted from a consensus recommendation for therapeutic drug monitoring of MMF after solid organ transplantation. 16 The calculated dose was rounded to 250 mg intervals. The schedule of drug dosing and AUC measurements is summarized in Figure 1 .
Regimen-related toxicity Regimen-related toxicity was scored using the Common Toxicity Criteria version 3 of the National Cancer Institute (http://ctep.cancer.gov/reporting/ctc.html). During the first 100 days after transplantation, we evaluated mucositis and neurological, gastrointestinal, hepatic, pulmonary and hematological toxicity. Any positive blood culture for pathogenic bacteria or candida species was documented as bacteremia or candidemia, respectively. Bacterial and yeast organ site infection as well as invasive mold infection required positive culture results from a biopsy taken at a sterile site or histologic evidence. The duration of hospitalization was recorded.
Engraftment and chimerism
Chimerism of PBLs was performed twice per week from engraftment until day 28 and weekly thereafter until day 100. Cellular DNA was amplified for at least three short tandem repeat loci. The amplified fragments were examined to identify informative host or donor markers, and the respective signals were quantified, as previously described. 17 
Supportive care
Tests for CMV pp65 antigen or PCR for CMV DNA were performed weekly. In case of a positive test result, preemptive therapy with ganciclovir 5 mg/kg q12 to 24 h was initiated and administered until PCR results became negative. Infectious disease prophylaxis strategies were employed during this study, including the use of systemic antibacterial antibiotics and fluconazole. All CMV seronegative patients received either screened or filtered blood Targeting mycophenolate mofetil for GVHD prophylaxis I Haentzschel et al products. Acyclovir was given for herpes simplex virus and VZV prophylaxis to seropositive patients for 1 month and 1 year, respectively.
Causes of death
Deaths after relapse were categorized as due to malignancy irrespective of the proximate cause. Deaths without relapse were categorized as non-relapse deaths. Infection was listed as the cause of death when a bacterial, viral or fungal infection was the proximate cause of death in patients who had not relapsed. GVHD was indicated as a contributor to death if active GVHD was present at the time of death from any cause in the absence of leukemia relapse.
Statistical analysis
The primary end point of the study was to determine the feasibility and toxicity of targeting MMF doses according to the plasma levels. Secondary end points included the incidence of donor stem cell engraftment, the incidence and severity of acute GVHD and the risk of persistent or recurrent disease. Acute GVHD was categorized clinically as Xgrade II, or grade III or IV according to the Glucksberg grading system. 18 Estimates of survival and disease-free survival were obtained by the method of Kaplan and Meier, where patients were censored at last follow-up if still alive. The incidences of relapse, nonrelapse mortality and acute GVHD were calculated using cumulative incidence estimates. 19 Non-relapse mortality and relapse were treated as competing risks.
Results

MPA pharmacokinetics and MMF doses
Area under the concentration and C max of MPA after 3 days of 2 Â 1500 mg i.v. are summarized in Figure 2 . Overall, 15 out of 29 patients evaluable (52%) achieved the target AUC with the initially prescribed dose. All other patients (n ¼ 14) required a dose increase on day 4 of the study protocol. After the second MPA measurement, one-third of the patients (n ¼ 10) still required a further dose increase, whereas a dose reduction was considered in one patient only. In the majority of patients (n ¼ 20, 69%) MMF doses could be adjusted to achieve the target AUC on day 11 after transplantation. Dose reduction was only performed in two cases on day 12, whereas dose increases were still required in seven patients (23%).
The maximum daily dose of MMF administered so far was 5 g b.i.d.
After first targeting on day 3, daily doses were increased to 3.5 g (n ¼ 3) and 4 g (n ¼ 11), and on day 7, they were increased to 3.5 g (n ¼ 1), 4 g (n ¼ 6), 4.5 g (n ¼ 3) and 5 g (n ¼ 1). As expected, we observed a significant correlation between C max and AUC for MPA in 28 patients evaluable at all time points (Po0.0001, R ¼ 0.48; Figure 3 ). The C max levels after about 2 h corresponding to the target AUC ranged between 16 and 25 mg/ml.
The median AUC 12 for MPA on days 3, 7 and 11 was 35.1, 41.3 and 43.1 mg/ml/h, respectively. For MPAG the corresponding values were 471, 551 and 652 mg/ml/h. No association between higher exposure toward MPAG and specific toxicities could be found. /l on three consecutive laboratory tests were reached after a median of 13 (range, 10-30) days. Platelet counts of X50 Â 10 9 /l were reached after a median of 13.5 (range 8-132) days. In one patient with myelodysplastic syndrome who died on day 30, engraftment had not occurred until death, although donor chimerism was complete on day 20. Chimerism tests showed timely engraftment donor hematopoiesis in all patients assayed. At 1 year, overall chimerism ranged between 95 and 100% (median 99.5%).
Regimen-related toxicity
Non-fatal and fatal toxicities associated with therapy are specified and graded in Table 2 . Non-fatal toxicities included: mucositis, colitis and sinusoidal obstruction syndrome/veno-occlusive disease of the liver. No infection with herpes simplex virus or VZV occurred during the first 100 days after transplantation. Out of 19 cases in which either patient and/or donor had been CMV seropositive, PCR-positivity requiring pre-emptive antiviral therapy was documented in 13 patients.
GVHD
Grades II to IV acute GVHD occurred in 16 (57%) out of 28 evaluable patients with onset between 5 and 61 (median 18) days (Figure 4 ). Grade III acute GVHD was observed in four (14%) patients, and four patients (14%) had grade IV acute GVHD. Two cases of hyperacute skin GVHD occurring before neutrophil engraftment was achieved. There was no detectable difference in the incidence and severity of acute GVHD between patients receiving a graft from related compared to unrelated donors. Twenty-four patients (83%) survived beyond day 100, and eight (33%) developed chronic GVHD that was extensive in five (19%) and limited in three patients.
Survival
The actuarial probability of overall survival and diseasefree survival are 46 and 38%, respectively (overall survival is shown in Figure 5a ). The Karnofsky performance score of the 15 surviving patients ranged between 60 and 100% (median 90%) by the time of last follow-up. There were nine deaths in patients who had not relapsed. Causes of death were bacterial sepsis (n ¼ 1), pneumonia (n ¼ 1), idiopathic pneumonia syndrome (n ¼ 2) and GVHD (n ¼ 5). The cumulative incidence of death without relapse was 12% at day 100 and 33% at 12 months (Figure 5b ).
Relapse
Malignancy persisted or recurred in six cases. One patient is alive after post transplant relapse and five died. The cumulative incidence of relapse was 19% (Figure 5b ).
Discussion
Mycophenolate mofetil has been successfully introduced into the field of allo-HSCT. Although not officially licensed, many investigators have used the compound to treat acute and chronic GVHD. 20, 21 In addition, MMF was shown to be synergistic with CYA in inducing a stable mixed chimerism after nonmyeloablative conditioning in a large animal model and in subsequent clinical studies. 22, 23 Studies on the use of MMF as part of GVHD prophylaxis have been limited in size and mostly inconclusive, as most investigators reported insufficient plasma levels of the active metabolite MPA. [3] [4] [5] 8, 24, 25 Most of these studies revealed a favorable toxicity profile of combinations of MMF with calcineurin inhibitors compared to regimens incorporating MTX. Encouraging results were reported by Nash et al., 7 who demonstrated that the rate of GVHD Targeting mycophenolate mofetil for GVHD prophylaxis I Haentzschel et al after transplantation from matched-sibling donors could be significantly reduced by using higher MMF doses up to 60 mg/kg daily. The optimum dose in this particular trial was 45 mg/kg, as higher doses induced toxicities without further reducing the risk of GVHD in recipients of grafts from matched siblings. In a study on the pharmacokinetics of MMF within the context of nonmyeloablative conditioning, application of MMF every 8 h was associated with a significantly higher MPA exposition and trough blood levels, which led to a decreased incidence of mixed T-cell chimerism and graft failure. 26 Unfortunately, the more profound state of immunosuppression led to an increased rate of CMV infections. A negative correlation between the rates of graft failure and GVHD and 6 h unbound MPA AUC has been described in a retrospective study providing further arguments for therapeutic drug monitoring. 27 Only recently, our results concerning shortened half-life and decreased MPA exposure in recipients of HSCTs have been confirmed by other investigators. 28 Tacrolimus combined with MMF has already been explored as GVHD prophylaxis in two trials after nonmyeloablative conditioning and in children receiving standard intensity regimens. Both groups concluded that the combination was effective and safe. 29, 30 Retrospective comparisons revealed that the rate of acute GVHD was at least comparable to standard CYA/MTX.
Therapeutic drug monitoring of MMF using simplified sampling strategies have been advocated after solid organ transplantation. 31 With this approach, most investigators hope to minimize the broad interpatient variability of MPA exposure especially in critically ill patients. The current investigation suggests that targeting of individual MMF doses according to the pharmacokinetic values is feasible in the early phase after allo-HSCT and allows for a controlled supply of MMF as a potentially efficient compound. Although significantly higher doses than previously reported were required to achieve the target AUC, no significant toxicity was specifically associated with the use of MMF. The most critical issue seems to be the early phase after transplantation during which levels tended to decrease in previous studies. This was in part compensated by the dose adaptation on day 4. But still, many patients achieved the targeted AUC level as late as day 11 after transplantation. This would argue for an intensified and more frequent pharmacokinetic targeting within the first 8-10 days, which is virtually impossible, when 12 h AUC have to be measured and calculated. Therefore, it was encouraging to see that AUC and C max levels had a promising coefficient of correlation, which would allow to minimize the daily measurements by just determining C max 2-3 h after starting the infusion and calculating the next dose to achieve levels between 16 and 30 mg/ml. This would allow for an intensification of the targeting regimen to achieve effective drug levels in the early phase after transplantation when GVHD effector cells are expanded.
One argument against MMF targeting could be the fact that the response to MMF is more correlated with the subtype of inosine monophosphate dehydrogenase isoenzyme of a certain cell type than with intracellular drug levels. In certain patients (10-15% of Caucasians), even AUC is probably not correlated with the immunosuppressive effects of MPA. It has to be discussed whether Targeting mycophenolate mofetil for GVHD prophylaxis I Haentzschel et al screening for inosine monophosphate dehydrogenase activity during MMF administration could be a future strategy to retain more reliable information on the optimum individual target drug level. 32, 33 The rate of acute GVHD in this series did not differ significantly from experiences with combinations of CYA or tacrolimus with MTX. Nevertheless, grade III-IV acute GVHD was observed in some cases. This fact may in part be attributed to the less consequent control of MPA plasma levels after patients had been switched to oral MMF and discharged to the outpatient department between days 14 and 21 after transplantation. In future trials, efforts will have to focus on optimum dosing of MMF from discharge until days 60-100. Probably, dosing every 8 h, and MPA measurements 2 h after the first morning dose can be helpful in this context. Our pharmacokinetic results do suggest that AUC targeting can be approximated by C max measurements, thereby making the overall approach more feasible. The current approach using 12 h kinetics is probably not feasible on a routine basis. New formulations of MMF might be of additional help in recipients of allo-HSCT to achieve higher plasma levels of MPA in the outpatient setting. 34 In conclusion, our study shows that individual MMF targeting according to AUC of MPA is feasible and effective in the early phase after allo-HSCT. The doses required to achieve the target AUC were not associated with dose-limiting toxicities. Given the high proportion of unrelated transplants, the rate of acute and chronic GVHD as well as the rate of overall survival seem to be acceptable. A modified daily dosing schedule in the outpatient setting seems to be warranted in future trials. Replacing AUC by C max targeting would lead to a more practical strategy probably also useful in the outpatient setting.
